This news article was originally written in Spanish. It has been automatically translated for your convenience. Reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace a human translator. The original article in Spanish can be viewed at El 93% de las empresas farmacéuticas rebaja su carga fiscal por dedicar recursos a la innovación

Index Lowendalmasaï on financials of the innovation in Spain

93% of the pharmaceutical companies discount his fiscal load for devoting resources to the innovation

Editorial Interempresas11/10/2012

The majority of the big companies of the pharmaceutical sector in Spain benefit of some type of fiscal discount for devoting resources to the innovation. 93% of the big companies of this sector uses any of the different possibilities offered by the Public Inland revenue to recess his load impositiva. Like this it has it it confirms the last report published by the skilled quality consultancy in optimisation of costs Lowendalmasaï, realised through a survey to 120 innovative companies of several sectors.

For Laura Thin, expert in Financials of the Innovation of the quality consultancy Lowendalmasaï, “the indirect helps have revealed like one of the most used tools by all type of companies, and the majority reinvierte in his own activities researchers the savings obtained by this lower fiscalidad”. The expert comments that this practical is greater in the pharmaceutical sector that in other sectors: “The Spanish companies of the pharmaceutical sector have showed his preference by the existent fiscal discounts by this concept, in front of the direct helps. Anyway, it suits to underline that almost the half of the companies polled benefits of some type of subsidy”. According to the study, 45% of the companies benefits of regional helps and 55%, of state.

Tools of financials in the pharmaceutical sector.

This preference of the Spanish companies for funding his innovation with indirect helps, explains Thin, is related with that Spain is one of the European countries in where more have prevailed these politics of fiscal discounts and this type of support to the innovation is being very employed by the big profitabilities that allows.

Other incentives infrautilizados

The survey remitted by the quality consultancy identifies a total of 7 types of incentives to the innovation delivered inside three groups: fiscal deductions, subsidies, and helps to the personal researcher. The first group includes deductions by R&D, Patent Box and amortización accelerated; the second, regional helps, national and international; and the third comprises subsidies of the program Inncorpora. In spite of the existence of this wide fan of possibilities the alimentary companies only use 4 of them: deductions R&D, regional and national helps and escasamente the Patent Box.

Thin explains this infrautilización of many of the incentives to the innovation by the complexity of gestión of the same: “The justification and administrative processing of many of these tools requires a deep knowledge and demands to allocate resources to his gestión by what a lot of companies centre in those less complex mechanisms and of more agile processing”. And it adds: “Sometimes it is a pity because with a correct gestión of the group of incentives the companies could achieve more resources for innovar, something fundamental to follow keeping the standard heights of quality reached by the Spanish pharmaceutical industry”.

Patent Box

Another of the conclusions of the study is the scarce utilisation of the Patent Box: so only 10,34% of the companies polled benefit of this fiscal tool. For Thin this tax incentive, is one of which would have to be more used by a greater number of companies of this sector. The expert explains that it could provide greater resources to the pharmaceutical companies road desgravaciones of the Tax of Societies since this mechanism allows a discount of 50% of the base imponible of the income declared by the cession intragrupo of determinate active intangible ('know how'). Thin: “it is one of the less used incentives and however can report interesting fiscal discounts, his complexity of processing does that it was one of the more strangers in east and in other sectors, however in Lowendalmasaï have the experience to surprise gratamente to our customers after checking the results of this mechanism”.

Data of the sample

The study on financials of the innovation, realised by the expert quality consultancy in optimisation of costs Lowendalmasaï, has been elaborated from a survey realised to 120 Spanish companies of average and big size, classified in 8 distinct sectors.